Gene detection equipment for congenital heart disease

Abstract

The invention belongs to the technical field of gene detection, and discloses gene detection equipment for congenital heart disease, which comprises a sample processing module, a gene amplification and enrichment module, a detection and analysis module, a user interaction module and a cloud data platform, the system realizes the integration of sample preparation, gene amplification, detection and analysis, reduces the manual operation steps and shortens the detection time. Multi-gene multi-site joint detection supports simultaneous detection of multiple gene sites, covers complex heritable variation of the congenital heart disease, and significantly improves detection specificity and sensitivity. Rapid detection and real-time diagnosis: the whole process from sample collection to result output is controlled within 2 hours, and the method is suitable for bedside detection of acute cases. By adopting the microfluidic and digital PCR technology, the detection equipment is miniaturized, so that the detection equipment is convenient to use by medical institutions or community clinics.

Description

Technical Field

[0001] The present invention belongs to the technical field of gene detection, and particularly relates to a gene detection device for congenital heart disease. Background Art

[0002] At present, most gene detection devices adopt detection technologies based on PCR (polymerase chain reaction) or gene chips, and usually need to isolate DNA samples, amplify gene fragments and then analyze. Although these methods are widely used in the field of gene detection, there are the following problems for the detection of congenital heart disease: Complex sample preparation: The detection device requires complex DNA extraction and purification steps, which takes a long time. Insufficient detection specificity: Congenital heart disease involves multiple gene mutations, and current detection devices cannot simultaneously detect mutations or structural abnormalities at multiple loci. Insufficient real-time diagnosis ability: Existing technologies are difficult to achieve bedside detection and cannot meet the needs of rapid diagnosis of acute cases. Low device integration: Common detection devices cannot complete the integrated operations of sample preparation, amplification and analysis, and the detection efficiency is low. There is an urgent need for a gene detection device that can be integrated and automated, reduce operation steps, improve detection efficiency, especially for the detection of multi-gene and multi-locus mutations related to congenital heart disease.

[0003] Through the above analysis, the problems and defects existing in the prior art are:

[0004] (1) Complex sample preparation: The detection device requires complex DNA extraction and purification steps, which takes a long time.

[0005] (2) Insufficient detection specificity: Congenital heart disease involves multiple gene mutations, and current detection devices cannot simultaneously detect mutations or structural abnormalities at multiple loci.

[0006] (3) Insufficient real-time diagnosis ability: Existing technologies are difficult to achieve bedside detection and cannot meet the needs of rapid diagnosis of acute cases.

[0007] (4) Low device integration: Common detection devices cannot complete the integrated operations of sample preparation, amplification and analysis, and the detection efficiency is low. Summary of the Invention

[0008] In view of the problems existing in the prior art, the present invention provides a gene detection device for congenital heart disease.

[0009] The present invention is implemented as follows. A gene detection device for congenital heart disease includes:

[0010] A sample processing module, a gene amplification and enrichment module, a detection and analysis module, a user interaction module, and a cloud data platform;

[0011] The sample processing module is connected to the gene amplification and enrichment module and the cloud data platform, and is used to complete the separation, DNA extraction and purification of blood samples using a microfluidic chip, and generate high-quality gene templates suitable for amplification;

[0012] The gene amplification and enrichment module is connected to the sample processing module, the detection and analysis module, the user interaction module, and the cloud data platform, and is used to amplify DNA templates using a digital PCR device and simultaneously achieve the enrichment of multiple genes and multiple loci;

[0013] The detection and analysis module is connected to the gene amplification and enrichment module and the user interaction module, and is used to obtain the amplified gene sequence based on nanopore sequencing technology and identify mutation sites through a data processing chip;

[0014] The user interaction module is connected to the gene amplification and enrichment module, the detection and analysis module, and the cloud data platform, and is used to provide visual detection results and display gene mutations and congenital heart disease risk assessments;

[0015] The cloud data platform is connected to the sample processing module, the gene amplification and enrichment module, and the user interaction module, and is used to compare the detection results with the cloud gene database and provide diverse gene analysis support.

[0016] The gene detection device for congenital heart disease consists of multiple functional modules. Some of the modules can use off-the-shelf commercial products, while some modules need to be custom-developed or integrated. The following is a detailed description of each module, including whether it can be purchased, specific parameters, and interface docking methods.

[0017] 1. Sample Processing Module

[0018] Function: Complete the separation, DNA extraction and purification of blood samples, and generate high-quality gene templates suitable for amplification.

[0019] Commercially available microfluidic chips and automated nucleic acid extractors can be purchased, or they can be custom-integrated.

[0020] Equipment used:

[0021] Microfluidic chip system (such as Fluidigm C1, Bio-Rad QX200)

[0022] Automated nucleic acid extractor (such as Qiagen QIAcube, Thermo Fisher KingFisher)

[0023] Key parameters:

[0024] Sample type: Peripheral blood (5 - 10 mL) or maternal plasma (NIPT)

[0025] Sample separation efficiency: >95% plasma recovery rate

[0026] DNA purity: A260 / A280 ratio of 1.8 - 2.0

[0027] Processing time: ≤30 min

[0028] Interface and docking:

[0029] Microfluidic chip interface: Standard microfluidic tubing (Luer interface)

[0030] Automated extractor interface: Supports USB / Ethernet connection to transfer data to the gene amplification module

[0031] 2. Gene amplification and enrichment module

[0032] Function: Use digital PCR (dPCR) or isothermal amplification (LAMP) technology for gene amplification and enrich target gene loci.

[0033] Commercially available dPCR or LAMP amplification equipment can be purchased, such as dPCR equipment from Bio-Rad and Thermo Fisher.

[0034] Equipment used:

[0035] Digital PCR (dPCR) system (such as Bio-Rad QX200, Stilla Naica)

[0036] Isothermal amplification equipment (such as Eppendorf Mastercycler)

[0037] Key parameters:

[0038] Target genes: GATA4, NKX2.5, TBX5, CHD7, FBN1, etc.

[0039] Detection sites: >1000 single nucleotide variations (SNVs) + copy number variations (CNVs)

[0040] DNA requirement: ≤10 ng (suitable for low-input DNA samples)

[0041] Reaction time: 30 - 60 min

[0042] Interface and docking:

[0043] Output format: qPCR / dPCR data file (CSV / JSON)

[0044] Data transfer interface: USB, WiFi, LAN (docked to the detection and analysis module)

[0045] 3. Detection and Analysis Module

[0046] Function: Analyze the amplified gene sequence based on Nanopore Sequencing technology and analyze the mutation sites through AI algorithms.

[0047] Commercially available nanopore sequencers (such as Oxford Nanopore MinION) can be purchased, or FPGA / ASIC chips can be customized for accelerated analysis.

[0048] Equipment used:

[0049] Nanopore sequencer (such as Oxford Nanopore MinION / GridION)

[0050] Data processing server (GPU / FPGA) (such as NVIDIA DGX, Intel Stratix 10 FPGA)

[0051] Key parameters:

[0052] Read length: 50bp - 10kb

[0053] Mutation detection sensitivity: >99%

[0054] Computing acceleration: Support for FPGA / ASIC hardware acceleration

[0055] Interfaces and docking:

[0056] Data format: FASTQ / BAM files (standard gene sequencing data format)

[0057] Data transfer protocol: USB3.1, Ethernet (docking to the user interaction module & cloud data platform)

[0058] 4. User Interaction Module

[0059] Function: Provide visualization of detection results, including gene mutations, congenital heart disease risk assessment, doctor's suggestions, etc.

[0060] Customized front - end UI and data display system are required. Off - the - shelf bioinformatics visualization software (such as Illumina BaseSpace, Geneious) can be used.

[0061] Equipment used:

[0062] Touch - screen terminal (Android / iOS)

[0063] Gene data visualization tool (Web - based)

[0064] Key parameters:

[0065] Supported data formats: CSV, JSON, BAM, VCF (variant data format)

[0066] Interaction method: Web / mobile application

[0067] Interfaces and docking:

[0068] REST API connection (for docking with the detection and analysis module)

[0069] WiFi / 4G connection (for docking with the cloud data platform)

[0070] 5. Cloud data platform

[0071] Functions: Provide mutation site database comparison, artificial intelligence risk assessment, and remote expert analysis support.

[0072] Ready-to-use bioinformatics cloud computing platforms (such as Google Genomics, AWS HealthLake) can be used, or local servers can be customized.

[0073] Devices used:

[0074] AWS / Azure / Google Genomics cloud platform

[0075] Local server (Linux HPC cluster)

[0076] Key parameters:

[0077] Data storage: Support PB-level storage

[0078] Computing power: Support AI model computing (TensorFlow / PyTorch)

[0079] Data security: Compliant with HIPAA / ISO 27001 standards

[0080] Interfaces and docking:

[0081] Data upload interfaces: HTTPS API, SFTP

[0082] Data analysis tools: GATK, DeepVariant, TensorFlow

[0083] Furthermore, the sample processing module:

[0084] 1) Blood samples are transported to the separation unit through the microfluidic channel (the main channel of the microfluidic chip);

[0085] 2) Under the action of the centrifugal force field, particle separation is carried out through Stokes' formula:

[0086]

[0087] Among them, v is the particle sedimentation velocity, r is the particle radius, ρ p , ρ f are the particle and fluid densities respectively, g is the acceleration due to gravity, and μ is the fluid viscosity;

[0088] 3) The separated DNA is captured on magnetic beads in a specific area, released by an eluent and then enters the purification unit to generate a high-purity DNA template.

[0089] Furthermore, the gene amplification and enrichment module:

[0090] 1) Distribute the template DNA to multiple micro reaction chambers, and each reaction chamber performs an independent PCR reaction to amplify the target gene fragment;

[0091] 2) According to the principle of real-time fluorescence detection, use the Michaelis-Menten kinetic model to monitor the amplification process:

[0092]

[0093] Among them, v is the amplification rate, Vmax is the maximum reaction rate, [S] is the template concentration, and Km is the equilibrium constant of the reactant concentration;

[0094] 3) The fluorescence signal intensity of digital PCR is used to calculate the initial concentration of the target gene fragment through the formula:

[0095]

[0096] Among them, C is the target gene concentration, F is the fluorescence signal, and k is the amplification efficiency factor.

[0097] Furthermore, the detection and analysis module:

[0098] 1) The sample DNA passes through the nanopore channel, and the base sequence information is obtained by using the current blocking effect; the change of the blocked current follows Ohm's law:

[0099]

[0100] Among them, I is the current passing through the nanopore, V is the voltage, R is the impedance, and the change of the impedance reflects the sequences of different bases;

[0101] 2) The data processing chip uses a dynamic decoding algorithm to identify the base sequence and generate a mutation site map of the target gene:

[0102]

[0103] Among them, M(i,j) is the mutation matrix, wk is the mutation weight, and f k (i,j) is the state of the gene locus.

[0104] Furthermore, the user interaction module:

[0105] 1) Receives the basic information of the patient and the detection requirements input by the doctor through the interaction interface;

[0106] 2) Calculates the risk of congenital heart disease through the Logistic regression model according to the gene analysis results:

[0107]

[0108] Among them, P is the probability of getting the disease, β0 is the bias term, and β i is the weight of the i-th gene locus, and x i is the gene mutation state.

[0109] Furthermore, the cloud data platform:

[0110] 1) Uploads the patient's mutant locus data to the cloud gene database through the interface;

[0111] 2) Calculates the posterior probability of the correlation between the patient's gene mutation and congenital heart disease based on the Bayesian inference model:

[0112]

[0113] Among them, P(A|B) is the risk probability of the patient's gene mutation, P(B|A) is the disease probability of similar mutations in the database, P(A) is the prior probability of gene mutation, and P(B) is the comprehensive probability of all diseases.

[0114] Another object of the present invention is to provide a gene detection method for congenital heart disease, including:

[0115] Step 1, using the microfluidic chip through the sample processing module to complete the separation, DNA extraction and purification of the blood sample, and generate a high-quality gene template suitable for amplification;

[0116] Step 2, using the digital PCR device through the gene amplification and enrichment module to amplify the DNA template, and simultaneously realizing the enrichment of multiple genes and multiple loci;

[0117] Step 3, obtaining the amplified gene sequence based on the nanopore sequencing technology through the detection and analysis module, and identifying the mutant locus through the data processing chip;

[0118] Step 4, providing a visual detection result through the user interaction module, and displaying the gene mutation and the risk assessment of congenital heart disease;

[0119] Step 5: Compare the detection results with the cloud gene database through the cloud data platform to provide diversified gene analysis support.

[0120] Combined with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solution to be protected by the present invention are as follows:

[0121] This system adopts a highly integrated automated detection process, utilizes microfluidic chips and digital PCR technology to achieve full-process automation of sample preparation, gene amplification, detection and analysis, and greatly reduces manual intervention. Through automated control and standardized operation procedures, the system can complete DNA extraction, gene amplification and sequencing in a short time, ensuring the high efficiency and consistency of detection, and is applicable to various clinical and rapid screening needs.

[0122] The system supports the combined detection of multiple genes and multiple loci, covering multiple key genes related to congenital heart disease (CHD) such as GATA4, NKX2.5, TBX5, CHD7, FBN1, etc. Through highly sensitive digital PCR and nanopore sequencing, it can simultaneously detect single nucleotide variations (SNVs), insertions and deletions (InDels) and copy number variations (CNVs), ensuring the comprehensiveness and accuracy of detection and improving the ability to analyze complex genetic variations.

[0123] Adopting efficient real-time data processing technology and combining with an AI bioinformatics analysis platform, the detection process can be completed within 2 hours, greatly improving the detection efficiency, applicable to point-of-care testing (POCT) for acute cases, and meeting the clinical demand for rapid gene detection. The detection results can be uploaded to the local terminal or cloud database in real time, supporting remote diagnosis and expert consultation, and facilitating precise medical decision-making.

[0124] This system integrates cloud big data analysis and personalized risk assessment functions. Based on mathematical models and machine learning algorithms, it can quantitatively analyze the risk of patient gene mutations and provide personalized diagnostic suggestions. Through a user-friendly operation interface, medical staff can quickly get started without complex training, applicable to hospitals at all levels, specialized institutions and community clinics, providing an efficient and convenient solution for the early screening and precise diagnosis and treatment of congenital heart disease, and having significant clinical value and industrialization potential. Brief Description of the Drawings

[0125] Figure 1 It is a structural block diagram of a gene detection device for congenital heart disease provided by an embodiment of the present invention.

[0126] Figure 2 It is a method flowchart of a sample processing module provided by an embodiment of the present invention.

[0127] Figure 3It is a flowchart of a gene detection method for congenital heart disease provided by an embodiment of the present invention.

[0128] Figure 1 Among them: 1. Sample processing module; 2. Gene amplification and enrichment module; 3. Detection and analysis module; 4. User interaction module; 5. Cloud data platform. Detailed implementation manners

[0129] In order to make the objectives, technical solutions and advantages of the present invention clearer and more understandable, the present invention will be further described in detail below in conjunction with embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0130] As Figure 1 shown, a gene detection device for congenital heart disease provided by an embodiment of the present invention includes:

[0131] Sample processing module 1, gene amplification and enrichment module 2, detection and analysis module 3, user interaction module 4, cloud data platform 5;

[0132] The sample processing module 1 is connected to the gene amplification and enrichment module 2 and the cloud data platform 5, and is used to complete the separation, DNA extraction and purification of blood samples by using a microfluidic chip, and generate a high-quality gene template suitable for amplification;

[0133] The gene amplification and enrichment module 2 is connected to the sample processing module 1, the detection and analysis module 3, the user interaction module 4, and the cloud data platform 5, and is used to amplify the DNA template by using a digital PCR device and simultaneously realize the enrichment of multiple genes and multiple loci;

[0134] The detection and analysis module 3 is connected to the gene amplification and enrichment module 2 and the user interaction module 4, and is used to obtain the amplified gene sequence based on nanopore sequencing technology and identify mutation sites through a data processing chip;

[0135] The user interaction module 4 is connected to the gene amplification and enrichment module 2, the detection and analysis module 3, and the cloud data platform 5, and is used to provide a visual detection result and display gene mutation and congenital heart disease risk assessment;

[0136] The cloud data platform 5 is connected to the sample processing module 1, the gene amplification and enrichment module 2, and the user interaction module 4, and is used to realize the comparison of the detection result with the cloud gene database and provide diversified gene analysis support.

[0137] The congenital heart disease gene detection device according to the embodiments of the present invention is based on a modular integrated design, realizing a fully automated detection process from blood sample processing to gene analysis. The sample processing module 1 is responsible for the separation, DNA extraction and purification of blood samples. Among them, a microfluidic chip is used to efficiently separate plasma, and high-purity cell-free DNA (cfDNA) is obtained by extraction with magnetic beads or silica gel membranes. This module can automatically regulate the temperature and reagent dosage to ensure the stability and consistency of DNA extraction, and transmit the DNA sample information to the gene amplification and enrichment module 2 through a data interface.

[0138] The gene amplification and enrichment module 2 uses digital PCR (dPCR) technology to perform isothermal amplification or high-throughput enrichment of target genes to ensure the detection sensitivity of low-concentration gene fragments. The built-in multiplex primer system of the system can simultaneously amplify multiple gene loci related to congenital heart disease, such as GATA4, NKX2.5, TBX5, CHD7, FBN1, etc., to achieve single-tube multi-gene detection. After amplification, the DNA sample directly enters the detection and analysis module 3, and the amplification data is uploaded through a high-speed data channel to ensure the continuity of detection.

[0139] The detection and analysis module 3 uses nanopore sequencing to perform long-read real-time sequencing on the amplification products, and combines FPGA / ASIC hardware acceleration computing to quickly identify genetic variations such as single nucleotide variations (SNVs), insertions and deletions (InDels), and copy number variations (CNVs). The AI algorithm automatically filters background noise and performs gene mutation analysis in combination with a local alignment database. The detection data is then transmitted to the user interaction module 4 for visual display, and at the same time, it can be compared and analyzed synchronously with the cloud data platform 5.

[0140] The user interaction module 4 provides a visual report, including gene mutation analysis, pathogenicity prediction, congenital heart disease risk assessment, etc. Medical staff can directly view the results through a touch screen, a Web interface or a mobile application. The cloud data platform 5 further optimizes the mutation interpretation, performs personalized risk prediction based on a machine learning model, and supports docking with international gene databases (such as ClinVar, HGMD) to improve the accuracy of detection results. The entire process can be completed within 2 hours, realizing non-invasive, rapid and high-throughput congenital heart disease gene detection.

[0141] As Figure 2 shown, the sample processing module provided by the embodiments of the present invention:

[0142] S101, the blood sample is transported to the separation unit through a microfluidic channel (the main channel of the microfluidic chip);

[0143] S102, under the action of a centrifugal force field, the particles are separated by Stokes' formula:

[0144]

[0145] Among them, v is the particle sedimentation velocity, r is the particle radius, ρ p , ρ f are the particle and fluid densities respectively, g is the acceleration due to gravity, and μ is the fluid viscosity;

[0146] S103, the separated DNA is captured on magnetic beads in a specific area, and after being released by the eluent, it enters the purification unit to generate a high-purity DNA template.

[0147] The gene amplification and enrichment module provided by the embodiments of the present invention:

[0148] 1) Distribute the template DNA to multiple micro reaction chambers, and each reaction chamber performs an independent PCR reaction to amplify the target gene fragment;

[0149] 2) According to the principle of real-time fluorescence detection, use the Michaelis-Menten kinetic model to monitor the amplification process:

[0150]

[0151] Among them, v is the amplification rate, Vmax is the maximum reaction rate, [S] is the template concentration, and Km is the equilibrium constant of the reactant concentration;

[0152] 3) The fluorescence signal intensity of digital PCR is used to calculate the initial concentration of the target gene fragment through the formula:

[0153]

[0154] Among them, C is the target gene concentration, F is the fluorescence signal, and k is the amplification efficiency factor.

[0155] The detection and analysis module provided by the embodiments of the present invention:

[0156] 1) The sample DNA passes through the nanopore channel, and the base sequence information is obtained by using the current blocking effect; the change of the blocked current follows Ohm's law:

[0157]

[0158] Among them, I is the current passing through the nanopore, V is the voltage, R is the impedance, and the change of the impedance reflects the sequence of different bases;

[0159] 2) The data processing chip uses a dynamic decoding algorithm to identify the base sequence and generate a mutation site map of the target gene:

[0160]

[0161] Among them, M(i,j) is the mutation matrix, wk is the mutation weight, and f k (i,j) is the state of the gene locus.

[0162] The user interaction module provided by the embodiment of the present invention:

[0163] 1) Receive the basic information of the patient and the detection requirements input by the doctor through the interaction interface;

[0164] 2) Calculate the risk of congenital heart disease through the Logistic regression model according to the gene analysis results:

[0165]

[0166] Among them, P is the probability of getting the disease, β0 is the bias term, and β i is the weight of the i-th gene locus, and x i is the gene mutation state.

[0167] The cloud data platform provided by the embodiment of the present invention:

[0168] 1) Upload the patient's mutation site data to the cloud gene database through the interface;

[0169] 2) Calculate the posterior probability of the correlation between the patient's gene mutation and congenital heart disease based on the Bayesian inference model:

[0170]

[0171] Among them, P(A|B) is the risk probability of the patient's gene mutation, P(B|A) is the disease probability of similar mutations in the database, P(A) is the prior probability of gene mutation, and P(B) is the comprehensive probability of all diseases.

[0172] As Figure 3 shown, a gene detection method for congenital heart disease provided by the embodiment of the present invention includes:

[0173] S201, use the microfluidic chip through the sample processing module to complete the separation, DNA extraction and purification of the blood sample, and generate a high-quality gene template suitable for amplification;

[0174] S202, use the digital PCR device through the gene amplification and enrichment module to amplify the DNA template, and at the same time realize the enrichment of multiple genes and multiple loci;

[0175] S203, obtain the amplified gene sequence based on the nanopore sequencing technology through the detection and analysis module, and identify the mutation sites through the data processing chip;

[0176] S204, provide visual detection results through the user interaction module, displaying gene mutations and congenital heart disease risk assessments;

[0177] S205, compare the detection results with the cloud gene database through the cloud data platform to provide diverse gene analysis support.

[0178] Through the sample processing module, the blood sample is separated into plasma by a microfluidic chip and DNA extraction and purification are carried out. This module utilizes the efficient fluid manipulation characteristics of microfluidic technology to automatically complete the whole process from sampling to generating high-quality DNA templates, ensuring the template purity and integrity for subsequent gene amplification. The DNA extraction unit combines chemical reagents to separate and purify the target DNA fragments in the blood sample and finally outputs a DNA template suitable for amplification.

[0179] In the gene amplification and enrichment module, a digital PCR device is used to simultaneously amplify multiple loci and multiple genes of the extracted DNA template. Digital PCR divides the DNA template through a microreaction system to ensure that each reaction unit has a single DNA molecule, thus achieving precise amplification and enrichment. This module can simultaneously amplify multiple genes and loci related to congenital heart disease, greatly improving the detection sensitivity and specificity.

[0180] The amplified DNA sample is subjected to high-throughput gene sequencing through the nanopore sequencing technology in the detection and analysis module. Nanopore sequencing uses current signals to detect the base arrangement of the DNA sequence and quickly obtains high-quality gene sequences. The data processing chip performs real-time analysis on the sequencing results and automatically identifies and quantifies the mutation site information. This process combines algorithms to compare with known congenital heart disease mutation sites and extracts key mutation information.

[0181] The detection results are presented on the device touch screen in real time through the user interaction module, including the detailed information of gene mutations and the congenital heart disease risk assessment results. At the same time, through the cloud data platform, the detection results are deeply compared and analyzed with the gene database to provide users with extended gene interpretation and disease risk assessment services. The cloud platform also supports long-term storage and diverse analysis of data, further improving the accuracy and flexibility of the detection system.

[0182] 1. Sample Processing Module

[0183] Function:

[0184] Use a microfluidic chip to complete the separation, DNA extraction and purification of blood samples, and generate high-quality gene templates suitable for amplification.

[0185] Working Principle:

[0186] 1. The blood sample is transported to the separation unit through a microfluidic channel (the main channel of the microfluidic chip).

[0187] 2. Under the action of the centrifugal force field, particle separation is carried out through Stokes' formula:

[0188]

[0189] Among them, v is the particle sedimentation velocity, r is the particle radius, ρ p , ρ f are the densities of the particle and the fluid respectively, g is the acceleration due to gravity, and μ is the fluid viscosity.

[0190] 3. The separated DNA is captured on magnetic beads in a specific area, released by the eluent and then enters the purification unit to generate a high-purity DNA template.

[0191] 2. Gene Amplification and Enrichment Module

[0192] Function:

[0193] Use a digital PCR device to amplify the DNA template and simultaneously achieve the enrichment of multiple genes and multiple loci.

[0194] Working principle:

[0195] 1. Distribute the template DNA to multiple micro reaction chambers, and each reaction chamber performs an independent PCR reaction to amplify the target gene fragment.

[0196] 2. According to the principle of real-time fluorescence detection, use the Michaelis-Menten kinetic model to monitor the amplification process:

[0197]

[0198] Among them, v is the amplification rate, Vmax is the maximum reaction rate, [S] is the template concentration, and Km is the equilibrium constant of the reactant concentration

[0199] 3. The fluorescence signal intensity of digital PCR is used to calculate the initial concentration of the target gene fragment through the formula:

[0200]

[0201] Among them, C is the target gene concentration, F is the fluorescence signal, and k is the amplification efficiency factor

[0202] 3. Detection and Analysis Module

[0203] Function:

[0204] Based on nanopore sequencing technology, obtain the amplified gene sequence and identify mutation sites through a data processing chip.

[0205] Working principle:

[0206] 1. The sample DNA passes through the nanopore channel, and the base sequence information is obtained by using the current blocking effect. The change of the blocked current follows Ohm's law:

[0207]

[0208] Among them, I is the current passing through the nanopore, V is the voltage, R is the impedance, and the change of the impedance reflects the sequences of different bases.

[0209] 2. The data processing chip uses a dynamic coding and decoding algorithm to identify the base sequence and generate a mutation site map of the target gene:

[0210]

[0211] Among them, M(i, j) is the mutation matrix, wk is the mutation weight, f k (i, j) is the state of the gene locus,

[0212] 4. User interaction module

[0213] Function:

[0214] Provide a visual detection result, showing gene mutations and risk assessment of congenital heart disease.

[0215] Working principle:

[0216] 1. Receive the basic information of the patient and the detection requirements input by the doctor through the interaction interface.

[0217] 2. According to the gene analysis results, calculate the risk of suffering from congenital heart disease through the Logistic regression model:

[0218]

[0219] Among them, P is the probability of suffering from the disease, β0 is the bias term, β i is the weight of the i-th gene locus, x i is the gene mutation state.

[0220] 5. Cloud data platform

[0221] Function:

[0222] Realize the comparison of the detection results with the cloud gene database and provide diversified gene analysis support.

[0223] Working principle:

[0224] 1. Upload the patient's mutation site data to the cloud gene database through the interface.

[0225] 2. Calculate the posterior probability of the correlation between the patient's gene mutation and congenital heart disease based on the Bayesian inference model:

[0226]

[0227] Among them, P(A|B) is the risk probability of the patient's gene mutation, P(B|A) is the disease probability of similar mutations in the database, P(A) is the prior probability of gene mutation, and P(B) is the comprehensive probability of all diseases.

[0228] Method steps:

[0229] Sample collection and preprocessing:

[0230] Obtain venous blood samples through a blood collection device and send them to the sample processing module.

[0231] Automatically extract and purify DNA in the microfluidic chip to generate high-quality gene templates.

[0232] Gene amplification:

[0233] Automatically import the sample into the amplification module and complete the enrichment and amplification of the target gene locus according to the preset primer sequence.

[0234] Gene sequencing and analysis:

[0235] The amplified gene fragments are rapidly sequenced through the nanopore sequencing module to obtain mutation information of multiple gene loci.

[0236] The data analysis module automatically matches the mutation information and generates a personalized detection report.

[0237] Result interpretation and output:

[0238] The user interface provides the detection results, including the detected mutation sites and the relevant congenital heart disease risk assessment.

[0239] The cloud data platform supports doctors to remotely access the detection reports and historical records.

[0240] Example 1: Non-invasive prenatal gene detection of congenital heart disease in high-risk fetuses

[0241] For pregnant women with a family history of congenital heart disease or high-risk pregnancy factors, non-invasive prenatal gene detection (NIPT) is used to screen the risk of congenital heart disease (CHD) in fetuses. By optimizing the detection process, high-sensitivity gene detection of maternal blood samples is achieved, and potential gene mutations in fetuses are identified early to assist clinical decision-making.

[0242] 1. Sample collection and processing

[0243] Using peripheral blood sampling technology, only 5 - 10 ml of peripheral blood from pregnant women needs to be collected. Maternal cell-free DNA (cfDNA) is efficiently isolated through a microfluidic chip, and DNA of fetal origin is extracted. This method does not require invasive procedures, reduces the risk to the fetus, and meets the screening requirements for early pregnancy (10 weeks and above).

[0244] 2. Gene Amplification and Detection

[0245] The extracted fetal DNA is enriched through ultra-low input DNA amplification technology, and digital PCR (dPCR) and nanopore sequencing are used for gene detection. The detection targets cover core genes known to be related to congenital heart disease (such as GATA4, NKX2.5, TBX5, CHD7, etc.). At the same time, copy number variation (CNV) analysis is combined to detect chromosomal structural abnormalities, comprehensively evaluating the genetic risk of the fetus.

[0246] 3. Data Analysis and Result Output

[0247] The sequencing data is automatically aligned with the reference database through a bioinformatics analysis system, screening for mutations related to the risk of congenital heart disease, and combining with a machine learning model to calculate the probability of the fetus having the disease. Finally, a personalized screening report is generated, including:

[0248] Target gene mutation information

[0249] Congenital heart disease risk assessment

[0250] Further diagnostic suggestions (such as echocardiogram or amniocentesis)

[0251] The entire detection process can be completed within 24 hours, enabling rapid screening.

[0252] Technical Advantages

[0253] Non-invasive and safe: Only maternal blood is required, with no risk of miscarriage.

[0254] High sensitivity: It can detect fetal DNA fragments in early pregnancy, detecting minor mutations and chromosomal abnormalities.

[0255] Early screening: Compared with echocardiogram (usually performed at 18 - 22 weeks), early intervention assessment can be carried out at 10 weeks and above.

[0256] Accurate detection: Combining single gene mutation + chromosomal abnormality screening to provide more comprehensive genetic information.

[0257] This method is applicable to pregnant women with a family history of congenital heart disease, gestational diabetes, advanced maternal age, or environmental exposure risks, providing early risk assessment for fetal health and a more accurate basis for doctors' prenatal management decisions.

[0258] Example 2: Large-scale Detection in Newborn Screening Programs

[0259] Applicable Scenarios:

[0260] For large-scale detection tasks in newborn screening programs, ensure rapid and efficient identification of mutation sites.

[0261] Operation Steps:

[0262] Sample Collection and Processing:

[0263] Collect a small amount of samples through heel prick blood and directly load them into an automated microfluidic device for processing.

[0264] Gene Amplification:

[0265] Use digital PCR technology to simultaneously amplify key sites in newborn gene samples, such as TBX5 and ZIC3 genes.

[0266] Gene Detection:

[0267] Introduce the amplified samples into the nanopore sequencing unit for batch sequencing and real-time acquisition of sequence data.

[0268] Data Analysis:

[0269] The data processing chip performs parallel processing on the gene data of multiple newborns, identifies mutation sites and groups them.

[0270] The cloud platform generates a population-based statistical report based on the comparison results and marks high-risk individuals.

[0271] Result Output:

[0272] Provide a newborn population screening report to medical institutions and view the detailed gene information of high-risk individuals in real time through the interactive interface.

[0273] Expected Effects:

[0274] Complete the gene screening of 500 newborns within one day, efficiently identify high-risk individuals, and provide key support for early intervention.

[0275] These two examples demonstrate the multi-scenario applicability of the present invention, including the ability for individualized detection and population screening, while highlighting its automated, rapid, and accurate characteristics.

[0276] The present invention is applicable to the fields of gene detection and precision medicine, and has wide applications especially in the detection of mutation sites related to congenital heart disease. Its specific application fields include:

[0277] 1) Newborn screening: The present invention can be used in large-scale newborn screening programs to rapidly detect high-risk gene mutations, providing precise support for early diagnosis and intervention.

[0278] 2) Personalized medicine: For patients with congenital heart disease, by precisely identifying gene mutation sites, individualized treatment and prevention plans can be formulated for patients.

[0279] 3) Genetic research: In the field of genetics, the high-throughput sequencing and multi-gene amplification technologies of the present invention can be applied to the study of mutation mechanisms and gene association analysis.

[0280] 4) Manufacture of gene detection devices: The modules in the present invention (such as microfluidic chips, nanopore sequencing units, digital PCR devices) can be used as independent products and promoted to the medical device and laboratory testing industries.

[0281] Evidence related to the technical effects obtained in the embodiments of the present invention.

[0282] 1) High-efficiency detection ability

[0283] In Example 2, the present invention demonstrated the ability to detect 500 samples within one day in newborn screening, significantly superior to traditional methods (usually taking several days or even weeks). Experimental data showed that the automated microfluidic device and digital PCR module of the present invention effectively shortened the sample processing and gene amplification time, and the sequencing accuracy reached over 99%.

[0284] 2) Multi-site and multi-gene synchronous detection

[0285] Through digital PCR and nanopore sequencing technologies, the present invention can simultaneously amplify and sequence multi-site gene mutations, especially suitable for key genes closely related to congenital heart disease such as TBX5 and ZIC3. Compared with traditional single-gene detection technologies, the detection efficiency is increased by more than 3 times.

[0286] 3) Precise mutation site identification

[0287] The data processing chip showed in multiple groups of experiments that the accuracy of its mutation site identification reached the base level. The comparison results with the known mutation site database showed that the mutation identification results of the present invention were consistent with the manually verified results by more than 98%.

[0288] 4) Cloud analysis support and data visualization

[0289] Experimental data showed that the cloud data platform could quickly complete the comparative analysis of detection results with the global gene database, generating population statistical reports and individualized gene interpretations. Through the real-time interactive interface, medical institutions could quickly locate high-risk individuals and view their detailed gene information, greatly improving the clinical decision-making efficiency.

[0290] In summary, through practical applications and experimental results, the present invention has verified its rapidity, accuracy, and versatility in the field of gene detection, and has significant technical advantages and industrial promotion value.

[0291] It should be noted that the implementation mode of the present invention can be realized through hardware, software, or a combination of software and hardware. The hardware part can be realized by using special logic; the software part can be stored in a memory and executed by an appropriate instruction execution system, such as a microprocessor or special designed hardware. Those of ordinary skill in the art can understand that the above-mentioned devices and methods can be realized by using computer-executable instructions and / or included in the processor control code. For example, such code is provided on a carrier medium such as a disk, CD, or DVD-ROM, a programmable memory such as a read-only memory (firmware), or a data carrier such as an optical or electronic signal carrier. The devices and modules of the present invention can be realized by hardware circuits of programmable hardware devices such as very large scale integrated circuits or gate arrays, semiconductors such as logic chips, transistors, etc., or programmable logic devices such as field programmable gate arrays, or can be realized by software executed by various types of processors, or can be realized by a combination of the above hardware circuits and software, such as firmware.

[0292] The above is only the specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention by those skilled in the art within the technical scope disclosed by the present invention should be covered by the protection scope of the present invention.

Claims

1. A gene detection device for congenital heart disease, characterized in that: include: The sample processing module is connected to the gene amplification and enrichment module and the cloud data platform to separate blood samples, extract and purify DNA using a microfluidic chip, and generate high-quality gene templates suitable for amplification; The gene amplification and enrichment module is connected with the sample processing module, the detection and analysis module, the user interaction module, and the cloud data platform, and is used to amplify the DNA template using a digital PCR device and simultaneously achieve the enrichment of multiple genes and multiple sites; The detection and analysis module is connected with the gene amplification and enrichment module and the user interaction module, and is used to obtain the amplified gene sequence based on the nanopore sequencing technology and identify the mutation site through the data processing chip; The user interaction module is connected with the gene amplification and enrichment module, the detection and analysis module, and the cloud data platform to provide visual test results, display gene mutations and congenital heart disease risk assessment; The cloud data platform is connected to the sample processing module, gene amplification and enrichment module, and user interaction module to compare the test results with the cloud gene database and provide diversified gene analysis support.

2. The gene detection device for congenital heart disease according to claim 1, characterized in that: The sample processing module: 1) The blood sample is transported to the separation unit through the microfluidic channel (the main channel of the microfluidic chip); 2) Under the action of centrifugal force field, the particles are separated by Stokes formula: Where v is the particle settling velocity, r is the particle radius, and ρ p ,ρ f are the particle and fluid densities, respectively, g is the gravitational acceleration, and μ is the fluid viscosity; 3) The separated DNA is captured on magnetic beads in specific areas, released by the elution solution and then enters the purification unit to generate a high-purity DNA template.

3. The gene detection device for congenital heart disease according to claim 1, characterized in that: The gene amplification and enrichment module: 1) The template DNA is distributed to multiple micro-reaction chambers, each of which performs an independent PCR reaction to amplify the target gene fragment; 2) Based on the principle of real-time fluorescence detection, the Michaelis-Menten kinetic model is used to monitor the amplification process: Where v is the amplification rate, Vmax is the maximum reaction rate, [S] is the template concentration, and Km is the equilibrium constant of the reactant concentration; 3) The fluorescence signal intensity of digital PCR is used to calculate the starting concentration of the target gene fragment using the formula: Among them, C is the target gene concentration, F is the fluorescence signal, and k is the amplification efficiency factor.

4. The gene detection device for congenital heart disease according to claim 1, characterized in that: The detection and analysis module: 1) The sample DNA passes through the nanopore channel and the base sequence information is obtained by using the current blocking effect; the change of the blocking current follows Ohm's law: Where I is the current passing through the nanopore, V is the voltage, and R is the impedance. The impedance change reflects the sequence of different bases; 2) The data processing chip uses a dynamic coding algorithm to identify the base sequence and generate a mutation site map of the target gene: Among them, M(i,j) is the mutation matrix, wk is the mutation weight, f k (i,j) is the state of the gene locus.

5. The gene detection device for congenital heart disease according to claim 1, characterized in that: The user interaction module: 1) Receive basic patient information and testing requirements input by doctors through the interactive interface; 2) Based on the results of gene analysis, the risk of congenital heart disease was calculated using a logistic regression model: Among them, P is the probability of illness, β0 is the bias term, and β i is the weight of the ith gene locus, x i The gene mutation status.

6. The gene detection device for congenital heart disease according to claim 1, characterized in that: The cloud data platform: 1) Upload the patient's mutation site data to the cloud gene database through the interface; 2) Based on the Bayesian inference model, calculate the posterior probability of the correlation between the patient's gene mutation and congenital heart disease: Among them, P(A|B) is the risk probability of the patient's gene mutation, P(B|A) is the disease probability of similar mutations in the database, P(A) is the prior probability of gene mutation, and P(B) is the comprehensive probability of all diseases.

7. A method for genetic detection of congenital heart disease using the genetic detection device for congenital heart disease according to any one of claims 1 to 6, characterized in that: The genetic testing method for congenital heart disease comprises: Step 1: Using a microfluidic chip through a sample processing module to separate blood samples, extract and purify DNA, and generate a high-quality gene template suitable for amplification; Step 2, amplifying the DNA template using a digital PCR device through a gene amplification and enrichment module, and achieving enrichment of multiple genes and multiple sites at the same time; Step 3, obtaining the amplified gene sequence through the detection and analysis module based on nanopore sequencing technology, and identifying the mutation site through the data processing chip; Step 4, providing visual test results through a user interaction module to display gene mutations and congenital heart disease risk assessment; Step 5: Compare the test results with the cloud gene database through the cloud data platform to provide diversified gene analysis support.

8. A computer device, characterized in that: The computer device includes a memory and a processor, wherein the memory stores a computer program, and when the computer program is executed by the processor, the processor executes the steps of the genetic detection method for congenital heart disease as claimed in claim 7.

9. A computer-readable storage medium storing a computer program, wherein when the computer program is executed by a processor, the processor executes the steps of the genetic detection method for congenital heart disease as claimed in claim 7.

10. An information data processing terminal, characterized in that: The information data processing terminal is used to implement the gene detection device for congenital heart disease as described in any one of claims 1-9.

Images